Status:
COMPLETED
Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Asthma
Eligibility:
All Genders
40+ years
Phase:
PHASE4
Brief Summary
The objective of this trial is to compare the total and regional deposition of aerosol in the lungs and oropharynx of patients with COPD and known poor MDI inhalation technique following inhalation of...
Detailed Description
This is a single dose, randomised, active-controlled, four period, open-label cross-over trial in adult patients with COPD who have demonstrated a poor MDI technique. Berodual (fenoterol hydrobromide ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- COPD patients: FEV1 less or equal 65% pre FEV1 less or equal 70% of FVC
- Exclusion criteria:
- Patients with any upper respiratory infection in the past 14 days prior to the screening visit (visit 1) Patients with any unstable or life-threatening cardiac arrhythmia
Exclusion
Key Trial Info
Start Date :
January 17 2006
Trial Type :
INTERVENTIONAL
End Date :
February 27 2006
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00267917
Start Date
January 17 2006
End Date
February 27 2006
Last Update
December 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Inamed Research GmbH & Co. KG
Gauting, Germany, 82131